Compare RYOJ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYOJ | SCYX |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 41.6M |
| IPO Year | N/A | 2014 |
| Metric | RYOJ | SCYX |
|---|---|---|
| Price | $2.41 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 31.4K | ★ 275.0K |
| Earning Date | 12-15-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | $274.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $0.57 |
| 52 Week High | $11.43 | $1.29 |
| Indicator | RYOJ | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 49.26 |
| Support Level | $1.89 | $0.68 |
| Resistance Level | $2.39 | $0.88 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 22.47 | 29.31 |
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.